Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | TGM2 | P21980 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1287190 | 0.72 | ALDH1A1 (0.50) | CYP1A2LMNAMEN1KMT2AGAA | |
| SCHEMBL11051 | 0.72 | CA12 (0.53) | CYP1A2TGM2LMNAMEN1KMT2A | |
| SCHEMBL16371883 | 0.72 | CA12 (0.53) | CYP1A2TGM2LMNAMEN1KMT2A | |
| SCHEMBL527139 | 0.71 | SMN1; SMN2 (0.42) | TGM2ADRB2ADRB1LMNAMEN1 | |
| SCHEMBL587239 | 0.71 | HSD17B10 (0.40) | CYP1A2TGM2LMNAMEN1KMT2A | |
| Bromide SCHEMBL30083679 | 0.70 | ALDH1A1 (0.47) | CYP1A2LMNAMEN1KMT2AGAA | |
| SCHEMBL253353 | 0.70 | CA12 (0.52) | CYP1A2TGM2LMNAMEN1KMT2A | |
| SCHEMBL10385905 | 0.70 | CA12 (0.52) | CYP1A2TGM2LMNAMEN1KMT2A | |
| SCHEMBL28296540 | 0.70 | CA12 (0.52) | CYP1A2TGM2LMNAMEN1KMT2A | |
| Water SCHEMBL10657216 | 0.70 | CA12 (0.52) | CYP1A2TGM2LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8592419-B2 | Ceramides and apoptosis-signaling ligand | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2013-11-26 | — | — | US | disclosed |
| US-20080045470-A1 | Ceramides and Apoptosis-Signaling Ligand | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045470-A1 | Ceramides and Apoptosis-Signaling Ligand | CERS2, S1PR1, S1PR3 | CYP1A2 3808/4885TGM2 3848/4885ADRB2 2265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.